



# Health Equity at Amgen: Outcomes within Reach

Addressing health disparities can help expand access to solutions and improve health outcomes for people in underserved communities. Doing so also allows us to gain unique perspectives and understanding that can help us better meet the needs of patients.

Amgen's efforts are guided by our health equity framework and informed by community partners, local healthcare organizations, patient advocacy groups, nonprofit leaders and Amgen employees. We will continue to evolve our framework and strategy in those areas where we believe we can have the greatest impact.

## Amgen Health Equity Framework & Strategy

<b>Our Vision</b>	Advance policies and practices in support of achieving health equity with the goal that all people have an opportunity to be as healthy as possible.		
<b>Key Focus Areas</b>	<b>Representative Product Development</b>	<b>Comprehensive Health Education</b>	<b>Accessible and Inclusive Healthcare</b>
<b>Our Objectives</b>	Work to address access to and participation in clinical trials and develop medicines to address unmet needs among historically underserved patients	Improve health literacy and education among historically underserved patients	Strengthen community and care support systems and access to medicines for historically underserved patients

### Our Approach

#### Learn from Lived Experiences:

Meaningfully embed representative patient perspectives into the development of our products and services.

#### Advance Solutions Through Partnerships:

Collaborate with trusted community organizations on bold initiatives to improve health disparities

#### Convene Powerful Conversations:

Foster solution-focused dialogue across the healthcare system to overcome systemic barriers to equitable health outcomes.

## Collaborations for Equitable Cardiovascular Health:

- **The Black Heart Association’s “Guard Your Heart” Tour** deploys mobile units at cultural events nationwide to screen 10,000 African Americans for elevated LDL-C and Lp(a) levels, providing education and follow-up care to those at high risk for cardiovascular disease (CVD).



- **Amgen’s Health Equity Challenge** is supporting efforts of five Florida-based nonprofits to improve CVD care among Black communities through education and access to cholesterol testing, treatment, and fitness and nutrition programs.



- Amgen and the **American Academy of Family Physicians (AAFP)** are collaborating to raise awareness and drive urgency around the importance of LDL cholesterol testing for those within the Hispanic community through a bilingual communications and educational campaign.

## Addressing Disparities in Lung Cancer Testing and Treatment:

- **HEAL Collaborative’s Small Cell Lung Cancer Community Conversations** hosted with faith-based organizations in U.S. cities with high smoking rates and dense African American populations emphasize screening importance and demystify the role of clinical trials in drug development.
- **LUNgevity’s ALABAMA ACCESS Pilot Project**, which aims to reduce disparities in access to advanced lung cancer care and precision medicine technologies by forming alliances with community oncology providers serving patients with lung cancer in counties with the highest lung cancer disparities, will provide a replicable framework to improve biomarker testing rates for other non-small cell lung cancer patients in Southern/Appalachian regions facing similar inequality.
- **The No One Left Alone Pilot Study** is evaluating biomarker testing access barriers driven by social determinants of health to create best practices for cancer centers serving ethnically diverse populations in Rural America.



## Achieving Clinical Trial Diversity and Representation

- **Amgen’s Representation in Clinical ReSEARCH (RISE) team** is addressing systemic issues that deter marginalized communities from participating in clinical research.



- Amgen is developing Diversity Action Plans for nearly every Phase 3 Amgen-sponsored clinical trial to support the inclusion of representative populations.
- The *Journal of Racial and Ethnic Health Disparities* published an Amgen analysis of the demographic diversity and representation of 31,619 participants across 258 of our U.S. clinical trials from 2012 to 2022. Known to date, Amgen is one of only four companies globally to disclose such data.

What we found: Compared to U.S. Census data, participants in Amgen clinical trials were more representative for Black or African Americans (17% in Amgen trials vs. 14% U.S. Census), but less representative for Asians (3% vs. 6%), American Indians or Alaska Natives (<1% vs. 1%), Native Hawaiians or other Pacific Islanders (<1% vs. 0.5%) or multiracial (<1% vs. 0.5%).

- Amgen is sponsoring the **African American Heart Study**, a unique community-based collaboration with the Association of Black Cardiologists (ABC) and the Morehouse School of Medicine (MSM), to address barriers to clinical trial access and better understand the increased cardiovascular disease risk associated with elevated Lp(a) levels in African Americans.

## Shining the Spotlight on Health Inequities:

- For over a decade, **Amgen’s Health Equity Summit** has united visionary leaders and passionate advocates to discuss solutions to health disparities through the exchange of actionable ideas and strategies.
- We are partnering with the Congressional Black Caucus Foundation, Congressional Hispanic Caucus Institute, and Asian Pacific American Institute for Congressional Studies to **lead discussions on health equity policy** and develop resources for the Quad Caucus of state legislators and public health officials. We are also working with GRANGE to advance rural health disparities.